In summary, our study underscores the therapeutic promise of KPT-330, an XPO1 inhibitor, for treating cutaneous T-cell lymphoma (CTCL). This evidence concerns the gene XPO1 and primary cutaneous T-cell non-Hodgkin lymphoma.